E-Newsletter
July 2016

ARTICLES

Fighting Cancer with targeted Drugs

“Diagnosis cancer” – this is a life-changing moment for many people. After cardiovascular diseases, cancer remains the next most common cause of death worldwide. In 2012, around 8.2 million people died as a result of cancer. According to the World Health Organization (WHO), this number will continue rising until 2030.

Th e Anti-Counterfeit Drug Issue; Its Real

Legislation is being put into place, but it is still essential that we all play a participative role in the continued fight to protect the patients that rely on our product.

NEWS

Advanced Clinical Receives Silver Award From Pro Unlimited Annual Global Supplier

Recipients of this award consistently deliver the highest standard of excellence, meeting the talent and project requirements of PRO's global Fortune 1000 customers.

Bayer and X-Chem Expand Drug Discovery Collaboration to Discover Novel Medicines

Bayer and X-Chem Inc ,a privately held biotechnology company focused on applying its innovative drug discovery capabilities to the generation of novel small molecule therapeutics, have entered into an expanded global drug discovery collaboration across multiple therapeutic areas and target classes.

PRESS RELEASES

Boehringer Ingelheim and University of Dundee collaborate to develop new class of medicines

Boehringer Ingelheim and the University of Dundee will join forces in an exciting collaboration with the aim to develop a novel class of medicines that target disease causing proteins for degradation.

Amgen And Daiichi Sankyo Announce Agreement To Commercialize Biosimilars In Japan

EAmgen and Daiichi Sankyo Company, Limited announced the execution of an exclusive agreement to commercialize nine biosimilars in Japan. The deal includes several biosimilars in late-stage development, including biosimilars of adalimumab.